Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Imatinib in Resected Primary GIST
NCT01172548Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2008
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoint: Recurrence Free Survival Rate at 2 years. Started Aug 2008; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT01172548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01172548.